Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II]
LBA4001 - Background: The IKF-575 trial investigates the long-standing question about the role of surgical intervention in limited-metastatic gastric / esophagogastric junction cancer after systemic induction therapy. Methods: Previously untreated patients (pts) with limited metastatic disease (retr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 05, 2024
|
| In: |
Journal of clinical oncology
Year: 2024, Jahrgang: 42, Heft: 17, Pages: LBA4001-LBA4001 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2024.42.17_suppl.LBA4001 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4001 Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4001 
|
| Verfasserangaben: | Salah-Eddin Al-Batran, Sylvie Lorenzen, Jorge Riera, Karel Caca, Christian Mueller, Daniel E Stange, Thomas Zander, Claus Bolling, Nils Homann, Jochen Gaedcke, Peter C. Thuss-Patience, Patrick Michl, Wolfgang Blau, Kai Wille, Christine Koch, Claudia Pauligk, Daniel Wilhelm Mueller, Ulli Simone Bankstahl, Stefan Paul Mönig, Thorsten Goetze |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 191944792X | ||
| 003 | DE-627 | ||
| 005 | 20250717000157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2024.42.17_suppl.LBA4001 |2 doi | |
| 035 | |a (DE-627)191944792X | ||
| 035 | |a (DE-599)KXP191944792X | ||
| 035 | |a (OCoLC)1528042545 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Batran, Salah-Eddin al- |e VerfasserIn |0 (DE-588)114597359 |0 (DE-627)626875730 |0 (DE-576)323432840 |4 aut | |
| 245 | 1 | 0 | |a Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction |b the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II] |c Salah-Eddin Al-Batran, Sylvie Lorenzen, Jorge Riera, Karel Caca, Christian Mueller, Daniel E Stange, Thomas Zander, Claus Bolling, Nils Homann, Jochen Gaedcke, Peter C. Thuss-Patience, Patrick Michl, Wolfgang Blau, Kai Wille, Christine Koch, Claudia Pauligk, Daniel Wilhelm Mueller, Ulli Simone Bankstahl, Stefan Paul Mönig, Thorsten Goetze |
| 264 | 1 | |c June 05, 2024 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2025 | ||
| 520 | |a LBA4001 - Background: The IKF-575 trial investigates the long-standing question about the role of surgical intervention in limited-metastatic gastric / esophagogastric junction cancer after systemic induction therapy. Methods: Previously untreated patients (pts) with limited metastatic disease (retroperitoneal lymph node (RPLN) metastases only or a maximum of one incurable organ site that is potentially resectable or locally controllable with or without retroperitoneal lymph nodes) received 4 cycles of FLOT, + trastuzumab if Her2+ or + nivolumab if PD-L1 positive. Pts without progression after 4 cycles were randomized to receive additional FLOT (Arm B) or radical complete surgical resection of primary and metastases followed by the same treatment (Arm A). It was planned to randomize 176 pts for which 271 pts had to enrolled. The primary endpoint was overall survival in the ITT population using Kaplan-Meier estimates. Recruitment was stopped after enrollment of 183 patients (141 patients randomized) with minimal impact on statistical power, due to a slow enrollment rate. Results: The ITT comprised 139 pts (A, 67; B, 72): 20% had RPLN metastases only, 58% organ metastases only, and 22% had both. Surgery in Arm A (ITT) was performed in 91% of pts and R0-resection rate (primary) was 82%. 30-d and 90-d mortalities in the surgery population were 3% and 8%. At least 4 additional cycles of post-op or post-randomization chemotherapy were achieved in 42% of pts in Arm A vs. 71% of pts in Arm B. The primary endpoint ovrall survival was not met due to increased early mortality in the surgery Arm leading to crossing survival curves with OS 25%- and 75%-Quantiles being 10 vs. 14 months and 65 vs. 41 months for Arms A vs. B, respectively. Pts with RPLN metastases only seemed to benefit most from the surgical approach (mOS, 30 vs. 17 months; 5y OS 38% vs. 19%; still having increased early mortality), while pts showing no response to chemo (mOS, 13 vs. 22 months) or pts with peritoneal disease (mOS, 12 vs. 19 months) derived a detrimental effect. Conclusions: The IKF-575/RENAISSANCE trial is negative but informs future research. Future protocols should focus on pts with RPLN only disease and exclude non-responding pts or those with peritoneal disease. There is a need for strategies against the early mortality caused by chemotherapy interruption. Clinical trial information: NCT02578368. | ||
| 700 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 700 | 1 | |a Riera, Jorge |e VerfasserIn |4 aut | |
| 700 | 1 | |a Caca, Karel |d 1963- |e VerfasserIn |0 (DE-588)12344733X |0 (DE-627)706303237 |0 (DE-576)171680065 |4 aut | |
| 700 | 1 | |a Müller, Christian |e VerfasserIn |0 (DE-588)1309906343 |0 (DE-627)187033521X |4 aut | |
| 700 | 1 | |a Stange, Daniel Eduard |d 1980- |e VerfasserIn |0 (DE-588)133390446 |0 (DE-627)691400105 |0 (DE-576)276050142 |4 aut | |
| 700 | 1 | |a Zander, Thomas |d 1971- |e VerfasserIn |0 (DE-588)123217342 |0 (DE-627)706213017 |0 (DE-576)293609403 |4 aut | |
| 700 | 1 | |a Bolling, Claus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Homann, Nils |e VerfasserIn |0 (DE-588)1350417475 |0 (DE-627)1910928887 |4 aut | |
| 700 | 1 | |a Gaedcke, Jochen Werner Christian |d 1977- |e VerfasserIn |0 (DE-588)124974910 |0 (DE-627)369616111 |0 (DE-576)294597476 |4 aut | |
| 700 | 1 | |a Thuss-Patience, Peter C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michl, Patrick |d 1971- |e VerfasserIn |0 (DE-588)121336328 |0 (DE-627)081239203 |0 (DE-576)292654677 |4 aut | |
| 700 | 1 | |a Blau, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wille, Kai |d 1978- |e VerfasserIn |0 (DE-588)133228568 |0 (DE-627)538691271 |0 (DE-576)299709620 |4 aut | |
| 700 | 1 | |a Koch, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pauligk, Claudia |d 1973- |e VerfasserIn |0 (DE-588)124633498 |0 (DE-627)363458352 |0 (DE-576)294422609 |4 aut | |
| 700 | 1 | |a Mueller, Daniel Wilhelm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bankstahl, Ulli Simone |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mönig, Stefan Paul |d 1963- |e VerfasserIn |0 (DE-588)172537665 |0 (DE-627)697473716 |0 (DE-576)133397750 |4 aut | |
| 700 | 1 | |a Götze, Thorsten |d 1976- |e VerfasserIn |0 (DE-588)131855964 |0 (DE-627)515807745 |0 (DE-576)298796600 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 42(2024), 17, suppl, Seite LBA4001-LBA4001 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II] |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:17 |g supplement:suppl |g pages:LBA4001-LBA4001 |g extent:1 |a Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II] |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4001 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4001 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250310 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121336328 |a Michl, Patrick |m 121336328:Michl, Patrick |d 910000 |d 910100 |e 910000PM121336328 |e 910100PM121336328 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 12344733X |a Caca, Karel |m 12344733X:Caca, Karel |d 50000 |e 50000PC12344733X |k 0/50000/ |p 4 | ||
| 998 | |g 128891106 |a Lorenzen, Sylvie |m 128891106:Lorenzen, Sylvie |d 50000 |e 50000PL128891106 |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN191944792X |e 4685782550 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Salah-Eddin Al-Batran, Sylvie Lorenzen, Jorge Riera, Karel Caca, Christian Mueller, Daniel E Stange, Thomas Zander, Claus Bolling, Nils Homann, Jochen Gaedcke, Peter C. Thuss-Patience, Patrick Michl, Wolfgang Blau, Kai Wille, Christine Koch, Claudia Pauligk, Daniel Wilhelm Mueller, Ulli Simone Bankstahl, Stefan Paul Mönig, Thorsten Goetze"]},"language":["eng"],"recId":"191944792X","person":[{"family":"Batran","role":"aut","given":"Salah-Eddin al-","display":"Batran, Salah-Eddin al-"},{"given":"Sylvie","display":"Lorenzen, Sylvie","role":"aut","family":"Lorenzen"},{"family":"Riera","role":"aut","given":"Jorge","display":"Riera, Jorge"},{"family":"Caca","role":"aut","display":"Caca, Karel","given":"Karel"},{"role":"aut","family":"Müller","given":"Christian","display":"Müller, Christian"},{"role":"aut","family":"Stange","display":"Stange, Daniel Eduard","given":"Daniel Eduard"},{"role":"aut","family":"Zander","display":"Zander, Thomas","given":"Thomas"},{"family":"Bolling","role":"aut","given":"Claus","display":"Bolling, Claus"},{"given":"Nils","display":"Homann, Nils","family":"Homann","role":"aut"},{"family":"Gaedcke","role":"aut","given":"Jochen Werner Christian","display":"Gaedcke, Jochen Werner Christian"},{"given":"Peter C.","display":"Thuss-Patience, Peter C.","family":"Thuss-Patience","role":"aut"},{"given":"Patrick","display":"Michl, Patrick","family":"Michl","role":"aut"},{"role":"aut","family":"Blau","display":"Blau, Wolfgang","given":"Wolfgang"},{"display":"Wille, Kai","given":"Kai","role":"aut","family":"Wille"},{"display":"Koch, Christine","given":"Christine","family":"Koch","role":"aut"},{"role":"aut","family":"Pauligk","display":"Pauligk, Claudia","given":"Claudia"},{"given":"Daniel Wilhelm","display":"Mueller, Daniel Wilhelm","family":"Mueller","role":"aut"},{"given":"Ulli Simone","display":"Bankstahl, Ulli Simone","family":"Bankstahl","role":"aut"},{"display":"Mönig, Stefan Paul","given":"Stefan Paul","role":"aut","family":"Mönig"},{"role":"aut","family":"Götze","given":"Thorsten","display":"Götze, Thorsten"}],"note":["Gesehen am 10.03.2025"],"title":[{"title_sort":"Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction","title":"Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction","subtitle":"the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II]"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"1 S."}],"id":{"doi":["10.1200/JCO.2024.42.17_suppl.LBA4001"],"eki":["191944792X"]},"relHost":[{"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"id":{"eki":["313116962"],"issn":["1527-7755"],"zdb":["2005181-5"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"313116962","titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"disp":"Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction the IKF-575/RENAISSANCE phase III trial : [Meeting Abstract: 2024 ASCO Annual Meeting II]Journal of clinical oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1983 -"],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"language":["eng"],"part":{"text":"42(2024), 17, suppl, Seite LBA4001-LBA4001","extent":"1","pages":"LBA4001-LBA4001","issue":"17","volume":"42","year":"2024"}}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"June 05, 2024"}]} | ||
| SRT | |a BATRANSALAEFFECTOFCH0520 | ||